<DOC>
	<DOCNO>NCT02049905</DOCNO>
	<brief_summary>The purpose study determine efficacy safety aldoxorubicin subject metastatic , locally advanced , unresectable soft tissue sarcoma .</brief_summary>
	<brief_title>Phase 3 Study Treat Patients With Soft Tissue Sarcomas</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>1 . Has provide write informed consent prior study related activity . 2 . Age ≥15 year ( US ) , 1880 ( rest world ( ROW ) ) , male female . 3 . Histological confirmation intermediate high grade softtissue sarcoma . Tissue must send central pathology lab review preclude entry onto study . Final assignment tumor grade histology base designation provide central pathology review . 4 . An adequate tumor specimen obtain either excisional biopsy , incisional biopsy core needle biopsy must send central pathology lab evaluation . The material must measure least 0.8 × 0.1 cm size contain least 50 tumor cell . 5 . Locally advanced , unresectable , and/or metastatic softtissue sarcoma intermediate high grade evidence disease progression either compute tomography ( CT ) magnetic resonance imaging ( MRI ) scan , clinical judgment last cancer therapy within 6 month prior randomization . 6 . Relapsed refractory ( lack response ) ≥1 course systemic therapy regimen ( ) , exclude adjuvant neoadjuvant chemotherapy , incurable either surgery radiation . 7 . Capable provide informed consent comply trial procedure . 8 . ECOG PS 02 . 9 . Life expectancy &gt; 12 week . 10 . Measurable tumor lesion accord RECIST 1.1 criterion . [ 50 ] 11 . Women must able become pregnant ( e.g. , postmenopausal least 1 year , surgically sterile , practice adequate birth control method ) duration study . ( Adequate contraception include : oral contraception , implanted contraception , intrauterine device implant least 3 month , barrier method conjunction spermicide . ) 12 . Males female partner ( ) childbearing potential must use 2 form effective contraception ( see Inclusion 11 plus condom vasectomy male ) last menstrual period female partner study treatment agree continue use 6 month final dose study treatment . 13 . Women child bear potential must negative serum urine pregnancy test Screening Visit nonlactating . 14 . Accessibility site optimize subject 's ability keep studyrelated appointment . 1 . Prior exposure &gt; 375 mg/m2 doxorubicin liposomal doxorubicin . 2 . Palliative surgery and/or radiation treatment within 30 day prior date randomization . 3 . Exposure investigational agent within 30 day date randomization . 4 . Exposure systemic chemotherapy within 30 day date randomization . 5 . An inadequate tumor specimen define central pathologist . 6 . Current evidence/diagnosis alveolar soft part sarcoma , extraskeletal myxoid chondrosarcoma , rhabdomyosarcoma , osteosarcoma , gastrointestinal stromal tumor ( GIST ) , dermatofibrosarcoma ( unless transform fibrosarcoma ) , Ewing 's sarcoma , Kaposi 's sarcoma , mixed mesodermal tumor , clear cell sarcoma . 7 . Evidence central nervous system ( CNS ) metastasis receive prior definitive therapy lesion . 8 . History malignancy except cure basal cell carcinoma , cutaneous squamous cell carcinoma , melanoma situ , superficial bladder cancer carcinoma situ cervix unless document free cancer ≥5 year . 9 . Laboratory value : Screening serum creatinine &gt; 1.5 x upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) &gt; 3×ULN &gt; 5×ULN liver metastasis present , total bilirubin &gt; 2×ULN , absolute neutrophil count ( ANC ) &lt; 1,500/mm3 , platelet concentration &lt; 100,000/mm3 , hemoglobin &lt; 9g/dL . 10 . Clinically evident congestive heart failure ( CHF ) &gt; class II New York Heart Association ( NYHA ) guideline . 11 . Current , serious , clinically significant cardiac arrhythmia , define existence absolute arrhythmia ventricular arrhythmia classify Lown III , IV V. 12 . Baseline QTc &gt; 470 msec and/or previous history QT prolongation take medication . 13 . Concomitant use medication associate high incidence QT prolongation allow . 14 . History sign active coronary artery disease without angina pectoris within last 6 month . 15 . Serious myocardial dysfunction define ECHO absolute leave ventricular ejection fraction ( LVEF ) institution 's low limit predict normal . 16 . Known history HIV infection . 17 . Active , clinically significant serious infection require treatment antibiotic , antiviral antifungal . The Medical Monitor contact uncertainty . 18 . Major surgery within 30 day prior date randomization . 19 . Current past substance abuse condition might interfere subject 's participation study evaluation study result . 20 . Any condition unstable could jeopardize subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>soft tissue sarcoma</keyword>
	<keyword>unresectable</keyword>
	<keyword>metastatic</keyword>
	<keyword>locally advanced</keyword>
	<keyword>sarcoma</keyword>
</DOC>